ValuEngine cut shares of TherapeuticsMD (NASDAQ:TXMD) from a buy rating to a hold rating in a report released on Wednesday morning.
Other analysts have also issued reports about the stock. Cantor Fitzgerald set a $27.00 price objective on shares of TherapeuticsMD and gave the company a buy rating in a research note on Monday, October 29th. Oppenheimer set a $14.00 price objective on shares of TherapeuticsMD and gave the company a buy rating in a research note on Wednesday, November 7th. reissued a buy rating and issued a $14.00 price target on shares of TherapeuticsMD in a research report on Tuesday, February 12th. BidaskClub raised shares of TherapeuticsMD from a sell rating to a hold rating in a research report on Tuesday, February 5th. Finally, Zacks Investment Research raised shares of TherapeuticsMD from a sell rating to a hold rating in a research report on Friday, November 2nd. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $14.45.
TXMD stock opened at $5.46 on Wednesday. The company has a quick ratio of 7.15, a current ratio of 7.23 and a debt-to-equity ratio of 0.55. TherapeuticsMD has a one year low of $3.51 and a one year high of $7.66. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -14.76 and a beta of 2.06.
In other news, CEO Robert G. Finizio sold 184,910 shares of the stock in a transaction that occurred on Thursday, December 20th. The shares were sold at an average price of $3.66, for a total value of $676,770.60. Following the completion of the sale, the chief executive officer now directly owns 18,458,559 shares of the company’s stock, valued at $67,558,325.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert G. Finizio sold 184,000 shares of the stock in a transaction that occurred on Tuesday, November 27th. The stock was sold at an average price of $4.83, for a total transaction of $888,720.00. Following the completion of the sale, the chief executive officer now directly owns 18,485,559 shares of the company’s stock, valued at $89,285,249.97. The disclosure for this sale can be found here. Insiders sold 1,953,675 shares of company stock valued at $8,839,611 over the last three months. 22.85% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of TXMD. Millennium Management LLC raised its position in TherapeuticsMD by 590.6% during the fourth quarter. Millennium Management LLC now owns 2,848,750 shares of the company’s stock valued at $10,854,000 after acquiring an additional 2,436,259 shares in the last quarter. FMR LLC raised its position in TherapeuticsMD by 14.7% during the third quarter. FMR LLC now owns 12,049,988 shares of the company’s stock valued at $79,048,000 after acquiring an additional 1,542,987 shares in the last quarter. BlackRock Inc. raised its position in TherapeuticsMD by 10.6% during the third quarter. BlackRock Inc. now owns 16,070,569 shares of the company’s stock valued at $105,421,000 after acquiring an additional 1,537,045 shares in the last quarter. Perceptive Advisors LLC bought a new position in TherapeuticsMD during the third quarter valued at approximately $9,840,000. Finally, Frontier Capital Management Co. LLC bought a new position in TherapeuticsMD during the fourth quarter valued at approximately $5,700,000. 75.10% of the stock is currently owned by hedge funds and other institutional investors.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Recommended Story: How analysts view the yield curve
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.